Literature DB >> 323387

Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.

V J Marder, R L Soulen, V Atichartakarn, A Z Budzynski, S Parulekar, J R Kim, N Edward, J Zahavi, K M Algazy.   

Abstract

A technique of quantitative venography has been developed in which values are assigned to the deep veins of the calf, knee, thigh, and pelvis, based upon the calculated volume and degree of occlusion of these venous segments. A maximum score of 40 units reflects complete thrombosis of all segments. This technique has been applied to a randomized, single-blind study of streptokinase versus heparin treatment. Each group of 12 patients had similar mean inital venographic scores; follow-up venograms were performed 5 days after the start of therapy. Streptokinase patients with high initial scores (larger than 20) showed a mean improvement of 12.1 units, while those with low initial scores(less than 20) were essentially unchanged. Heparin patients with high scores had a minimal mean improvement of 1.1 units, but those with low scores had a significant mean extension of thrombosis of 8.6 units. Patients with symptoms for less than 7 days showed greated mean improvement (12.7 units) with streptokinase that those with a longer duration of symptoms (2.0 units); heparin patients in these subgroups showed a mean worsening of 7.5 units and no change, respectively. Extrinsic venous obstruction by tumor did not prevent an excellent response to streptokinase. No single test of coagulation of fibriolysis was a reliable indicator of the degree of venographic response to lytic therapy. Pyrexia and hemorrhagic complications occurred in over one-half of the streptokinase patients; one had an anaphylactic reaction, and one died of intracerebral hemorrhage during therapy. The data suggest that lytic therapy is best restricted to the patient with acute extensive thrombosis. Also, continuous infusions of heparin according to current guidelines may be inadequate to prevent thrombus growth in some patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 323387

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  33 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Why thrombolytic therapy.

Authors:  S Sherry
Journal:  West J Med       Date:  1981-02

3.  Anticoagulant therapy.

Authors:  J M Teitel
Journal:  Can Fam Physician       Date:  1984-09       Impact factor: 3.275

4.  Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis.

Authors:  Anthony J Comerota; Clive Kearon; Chu-Shu Gu; Jim A Julian; Samuel Z Goldhaber; Susan R Kahn; Michael R Jaff; Mahmood K Razavi; Andrei L Kindzelski; Riyaz Bashir; Parag Patel; Mel Sharafuddin; Michael J Sichlau; Wael E Saad; Zakaria Assi; Lawrence V Hofmann; Margaret Kennedy; Suresh Vedantham
Journal:  Circulation       Date:  2019-02-26       Impact factor: 29.690

5.  Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII.

Authors:  C W Francis; V J Marder
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

6.  Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.

Authors:  Igor A Suchkov; Javier Martinez-Gonzalez; Sebastian M Schellong; Toni Garbade; Michela Falciani
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

7.  Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.

Authors:  Ariel Izcovich; Juan M Criniti; Federico Popoff; Liming Lu; Jiaming Wu; Walter Ageno; Daniel M Witt; Michael R Jaff; Sam Schulman; Veena Manja; Peter Verhamme; Gabriel Rada; Yuqing Zhang; Robby Nieuwlaat; Wojtek Wiercioch; Holger J Schünemann; Ignacio Neumann
Journal:  Blood Adv       Date:  2020-04-14

8.  Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis.

Authors:  Suresh Vedantham; Samuel Z Goldhaber; Susan R Kahn; Jim Julian; Elizabeth Magnuson; Michael R Jaff; Timothy P Murphy; David J Cohen; Anthony J Comerota; Heather L Gornik; Mahmood K Razavi; Lawrence Lewis; Clive Kearon
Journal:  Am Heart J       Date:  2013-03-05       Impact factor: 4.749

9.  Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.

Authors:  A Leizorovicz; G Simonneau; H Decousus; J P Boissel
Journal:  BMJ       Date:  1994-07-30

10.  Immunology of streptokinase in human subjects.

Authors:  K McGrath; R Patterson
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.